Newsroom

Filter By:
340B In The News

Fierce Healthcare: Appeals court upholds nearly 30% payment cut to 340B hospitals

A federal appeals court has ruled the Trump administration can install nearly 30% cuts to the 340B drug discount program.
July 1, 2020
340B In The News

RealClearHealth: Congress Has no Clue About What’s Driving up Drug Prices

A coalition of think tanks and health care organizations – dubbed Lower Drug Prices Now – just launched a campaign to promote price controls on coronavirus treatments in development. Several Democratic House leaders want such language included in future stimulus packages.
June 4, 2020
340B In The News

RealClearHealth: Hospitals Are Gaming the 340B Drug Program

The COVID-19 crisis has been a brutal lesson on the limitations of government action and imagination. The response, thus far, has been a ‘business as usual’ expansion of entitlements and interventions in an attempt for the government (programs, loans, direct payments, welfare, food assistance, etc.) to take the place of private sector activity. It has not worked.
May 21, 2020
340B In The News

Hospitals Serving Vulnerable Communities Chase Profits at the Expense of Patients

Patients across the country are receiving hospital care not knowing if they will get stuck with enormous and unexpected bills when they are released.
February 27, 2020
340B In The News

Becker’s: Lax oversight causing drugmakers to dish out duplicate 340B, Medicaid discounts, GAO finds

Lax oversight by the federal government is causing drugmakers to pay discounts for the same drug twice, according to a new report released this week from the U.S. Government Accountability Office.
January 29, 2020
340B In The News

Fierce Healthcare: GAO: Feds have to improve oversight to stop drug companies from doling out duplicate 340B, Medicaid discounts

The federal government isn't doing a good job of determining whether a drug company has to provide both 340B discounts and rebates for Medicaid, a federal watchdog said.
January 28, 2020
340B In The News

New Study Finds Hospitals Charge Nearly Two Times More Than Physician Offices for Same Cancer Treatments

WASHINGTON – New research from the Employee Benefit Research Institute (EBRI) has concluded that payments from private third-party payers for infused cancer medicines are, on average, twice as much when care is provided in hospital outpatient departments (HOPDs) compared with physician offices (POs). In fact, the findings demonstrate that on a medication- by-medication basis, HOPDs charged up to 4.3 times more than physician offices for the same cancer treatment. Notably, the disparity is due to hospital pricing practices and not the quality of care provided or progression of the disease, according to the issue brief.
January 22, 2020
340B In The News

New GAO Report Finds Oversight Lacking For 340B Hospitals

new report from the Government Accountability Office (GAO) has concluded increased oversight is needed to ensure nongovernmental hospitals meet 340B eligibility requirements.
January 15, 2020
Scroll to Top